295 related articles for article (PubMed ID: 19875936)
21. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
[TBL] [Abstract][Full Text] [Related]
22. Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.
Singh N; Pandey A; Mittal SK
Expert Rev Mol Med; 2010 Apr; 12():e14. PubMed ID: 20426889
[TBL] [Abstract][Full Text] [Related]
23. Improving the selection and development of influenza vaccine viruses - Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18-20 November 2015.
Hampson A; Barr I; Cox N; Donis RO; Siddhivinayak H; Jernigan D; Katz J; McCauley J; Motta F; Odagiri T; Tam JS; Waddell A; Webby R; Ziegler T; Zhang W
Vaccine; 2017 Feb; 35(8):1104-1109. PubMed ID: 28131392
[TBL] [Abstract][Full Text] [Related]
24. Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus.
Ding H; Tsai C; Zhou F; Buchy P; Deubel V; Zhou P
PLoS One; 2011 Mar; 6(3):e17821. PubMed ID: 21464977
[TBL] [Abstract][Full Text] [Related]
25. The threat of avian influenza A (H5N1). Part IV: Development of vaccines.
Cinatl J; Michaelis M; Doerr HW
Med Microbiol Immunol; 2007 Dec; 196(4):213-25. PubMed ID: 17541633
[TBL] [Abstract][Full Text] [Related]
26. Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.
Hasegawa H; Ichinohe T; Tamura S; Kurata T
Expert Rev Vaccines; 2007 Apr; 6(2):193-201. PubMed ID: 17408369
[TBL] [Abstract][Full Text] [Related]
27. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection.
Giles BM; Crevar CJ; Carter DM; Bissel SJ; Schultz-Cherry S; Wiley CA; Ross TM
J Infect Dis; 2012 May; 205(10):1562-70. PubMed ID: 22448011
[TBL] [Abstract][Full Text] [Related]
28. Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms.
Luke CJ; Subbarao K
Expert Rev Vaccines; 2014 Jul; 13(7):873-83. PubMed ID: 24855993
[TBL] [Abstract][Full Text] [Related]
29. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza.
Landry N; Ward BJ; Trépanier S; Montomoli E; Dargis M; Lapini G; Vézina LP
PLoS One; 2010 Dec; 5(12):e15559. PubMed ID: 21203523
[TBL] [Abstract][Full Text] [Related]
30. Cell-cultured, live attenuated, X-31ca-based H5N1 pre-pandemic influenza vaccine.
Lee YH; Jang YH; Seong BL
Virology; 2017 Apr; 504():73-78. PubMed ID: 28157547
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
Crowe BA; Brühl P; Gerencer M; Schwendinger MG; Pilz A; Kistner O; Koelling-Schlebusch K; Aichinger G; Singer J; Zeitlinger M; Müller M; Ehrlich H; Barrett PN
Vaccine; 2010 Dec; 29(2):166-73. PubMed ID: 21055500
[TBL] [Abstract][Full Text] [Related]
32. Adenovirus-based vaccines against avian-origin H5N1 influenza viruses.
He B; Zheng BJ; Wang Q; Du L; Jiang S; Lu L
Microbes Infect; 2015 Feb; 17(2):135-41. PubMed ID: 25479556
[TBL] [Abstract][Full Text] [Related]
33. Aflunov(®): a prepandemic influenza vaccine.
Gasparini R; Amicizia D; Lai PL; Panatto D
Expert Rev Vaccines; 2012 Feb; 11(2):145-57. PubMed ID: 22309663
[TBL] [Abstract][Full Text] [Related]
34. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
[TBL] [Abstract][Full Text] [Related]
35. Establishment of Vero cell RNA polymerase I-driven reverse genetics for Influenza A virus and its application for pandemic (H1N1) 2009 influenza virus vaccine production.
Song MS; Baek YH; Pascua PNQ; Kwon HI; Park SJ; Kim EH; Lim GJ; Choi YK
J Gen Virol; 2013 Jun; 94(Pt 6):1230-1235. PubMed ID: 23486669
[TBL] [Abstract][Full Text] [Related]
36. Vaccines for pandemic influenza.
Luke CJ; Subbarao K
Emerg Infect Dis; 2006 Jan; 12(1):66-72. PubMed ID: 16494720
[TBL] [Abstract][Full Text] [Related]
37. Strategies for developing vaccines against H5N1 influenza A viruses.
Horimoto T; Kawaoka Y
Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
[TBL] [Abstract][Full Text] [Related]
38. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.
Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ
Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770
[TBL] [Abstract][Full Text] [Related]
39. Clinical vaccine development for H5N1 influenza.
Clegg CH; Rininger JA; Baldwin SL
Expert Rev Vaccines; 2013 Jul; 12(7):767-77. PubMed ID: 23885822
[TBL] [Abstract][Full Text] [Related]
40. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
